Nexus Pharmaceuticals Launches New Cyclophosphamide Injection

The drug is now available in 2.5 mL and 5 mL ready-to-dilute vials.

Apr. 7, 2026 at 7:08am

Got story updates? Submit your updates here. ›

An extreme close-up X-ray photograph revealing the intricate internal structure of a glass vial filled with a glowing, ghostly liquid medication, conceptually illustrating the scientific and clinical nature of this new pharmaceutical product.The launch of a new generic version of the critical chemotherapy drug Cyclophosphamide aims to expand access to this important treatment option for cancer patients.Lincolnshire Today

Nexus Pharmaceuticals, a US-based healthcare company, has announced the launch of Cyclophosphamide Injection, a critical chemotherapy medication that slows the growth of cancer cells. The drug is now available in 2.5 mL and 5 mL ready-to-dilute multiple-dose vials, providing healthcare providers with an important treatment option.

Why it matters

Cyclophosphamide is a widely used chemotherapy drug, and the launch of this new generic version helps expand access to this critical medication for cancer patients. Nexus specializes in developing difficult-to-manufacture specialty and generic drugs, ensuring a reliable supply of important treatments.

The details

Nexus Pharmaceuticals' Cyclophosphamide Injection is the first AP Rated Generic to Dr. Reddy's version of the drug. The new product is available in 500 mg/2.5 mL and 1 gram/5 mL formulations, providing healthcare providers with more options to meet patient needs. Nexus is committed to transforming difficult-to-formulate molecules into high-quality medicines and expanding access to critical treatments.

  • Cyclophosphamide Injection is now available for order.

The players

Nexus Pharmaceuticals, LLC

A US-based healthcare company that specializes in innovative processes to make difficult-to-manufacture specialty and generic drugs.

Stephen Kim

Chief Executive Officer at Nexus Pharmaceuticals.

Got photos? Submit your photos here. ›

What they’re saying

“Transforming difficult-to-formulate molecules into the highest-quality medicines is what we do best.”

— Stephen Kim, Chief Executive Officer

The takeaway

The launch of Nexus Pharmaceuticals' new Cyclophosphamide Injection helps expand access to this critical chemotherapy medication, providing healthcare providers with more options to treat cancer patients. Nexus' focus on developing difficult-to-manufacture drugs ensures a reliable supply of important treatments.